MINNEAPOLIS--(BUSINESS WIRE)--DaVita Clinical Research® (DCR®), a provider of clinical research services focused on kidney research as well as a multitude of specialty therapeutic populations, today announced the company’s recent investment in its Central Laboratory, servicing pharmaceutical, biotechnology and medical device industries.
The investment was applied to analytical methodology, information technology (IT) and instrumentation in support of DCR’s continued drive to serve its clients. Over the past three years, DCR has had a strategic focus on Central Laboratory services, investing in state-of-the-art capital equipment, infrastructure and laboratory expansion/remodeling. The investment was placed in DCR’s Central Laboratory to ensure continuous delivery of customized care and satisfaction to its patients.
The Central Laboratory uses the latest in laboratory instrumentation to provide rapid, accurate results. Some examples of the lab’s instrumentation and ever-increasing test menu include:
- 7 Olympus 5400
- 17 Siemens Centaur
- 9 Tosoh G-8
- 2 Liaison Diasorin
- 8 Perkin-Elmer ICP-MS
- 2 Nova
- 2 Dianex
- 23 Siemens Advia 2120
- 2 TOPS Coagulation
- 19 BACTEC 9240
- 14 Lonza BioTek
- 4 Vitek-2
DCR’s Central Laboratory also has invested in such technology as centrifuges, auto samplers, slide strainers, incubators, biosafety cabinets and decappers. DCR’s investment assisted in expanding and remodeling the laboratory, adding significant space to help facilitate future service expansion. In addition, extensive investment in its Falcon LabTM software application has resulted in the latest release, which includes an industry-leading report package.
At DCR’s Central Laboratory, individual trial samples are tracked using LabScope Online®, a leading-edge order-entry and reporting system designed to streamline lab processes while maintaining strict quality assurance. Additional services include the new, innovative green packaging capabilities featuring a unique IATA-compliant, storage-friendly design, and the lab’s highly dedicated customer support team, which ensures most specimen turnaround time of 24 hours or less.
“DCR’s Florida-based Central Laboratory facility is one of the industry’s best kept secrets,” said DCR Vice President, Commercial Development Kevin J. Goudreau. “We are confident that, over time, our continued investments in both physical assets and an expanded assay list will position us to be a prominent player in the clinical trials support business.”
The DCR Central Laboratory team is led by experienced medical technologists, medical technicians and clinical pathologists, and receives formal guidance from top nephrologists in the industry.
DaVita, DaVita Clinical Research, DCR and Falcon Lab are trademarks or registered trademarks of DaVita, Inc. All other trademarks are the property of their respective owners.
About DaVita Clinical Research (DCR)
DaVita Clinical Research (DCR) is committed to advancing the knowledge and practice of kidney care. DCR brings unsurpassed knowledge, skill, and expertise to pharmaceutical research, facilitating the success of their clients’ clinical trials. DCR’s clinical expertise ranges from designing the study to preparing and submitting the final report. DCR’s Early Clinical Research unit (Phase I-IIa) and Clinical Development network of physicians and investigative sites, Health Economics and Central Laboratory are focused on providing world-class clinical research in both complex/specialty populations and therapeutic areas as well as CKD and ESRD populations needed to meet clinical goals. To learn more about DCR, visit www.davitaclinicalresearch.com.
About DaVita
DaVita Inc., a Fortune 500® company, is a leading provider of kidney care in the United States, delivering dialysis services and education to patients with chronic kidney failure and end stage renal disease. As of March 31, 2011, DaVita operated or provided administrative services at 1,642 dialysis facilities, serving approximately 128,000 patients. DaVita develops, participates in and donates to numerous programs dedicated to transforming communities and creating positive, sustainable change for children, families and our environment. The company’s leadership development initiatives and corporate social responsibility efforts have been recognized by Fortune, Modern Healthcare, Newsweek and WorldBlu, among others. For more information, please visit www.davita.com.